Loading...
•
Mar 31, 2024
Avadel Q1 2024 Earnings Report
Reported a strong quarter with LUMRYZ launch and pipeline advancements.
Key Takeaways
Avadel Pharmaceuticals reported $27.2 million in net product revenue from LUMRYZ sales in Q1 2024. The company is focused on expanding the market for LUMRYZ and advancing its pipeline, including a Phase 3 trial in idiopathic hypersomnia.
Generated $27.2 million in net revenue from sales of LUMRYZ™.
Over 2,800 patients enrolled in Avadel’s RYZUP patient support services, with more than 1,700 patients initiating therapy.
Pursuing expansion opportunities for LUMRYZ with sNDA in pediatric narcolepsy.
On track to enroll first patient in a Phase 3 pivotal idiopathic hypersomnia trial in the second half of 2024.
Revenue by Segment
Forward Guidance
Avadel is focused on the continued market growth of LUMRYZ for the treatment of narcolepsy as well as potentially expanding to the pediatric population and initiating their Phase 3 pivotal trial in idiopathic hypersomnia in the second half of the year.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...